113
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Is there any correlation among MKK4 (mitogen-activated protein kinase kinase 4) expression, clinicopathological features, and KRAS/NRAS mutation in colorectal cancer

, , ORCID Icon, ORCID Icon, , & ORCID Icon show all
Pages 851-859 | Received 01 Feb 2020, Accepted 16 Jun 2020, Published online: 13 Jul 2020

References

  • English J, Pearson G, Wilsbacher J, et al. New insights into the control of MAP kinase pathways. Exp Cell Res. 1999 Nov 25;253(1):255–270.
  • Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001 Mar 1;410(6824):37–40.
  • Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000 Oct 13;103(2):239–252.
  • Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene. 2007 May 14;26(22):3172–3184.
  • Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005 Jan;15(1):11–18.
  • Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle (Georgetown, Tex). 2003 May-Jun;2(3):199–201.
  • Ganiatsas S, Kwee L, Fujiwara Y, et al. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Nat Acad Sci. 1998;95(12):6881–6886.
  • Hilberg F, Aguzzi A, Howells N, et al. c-Jun is essential for normal mouse development and hepatogenesis. Nature. 1993 [ 1993 09 01];365(6442):179–181.
  • Yoshida BA, Dubauskas Z, Chekmareva MA, et al. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999;59(21):5483–5487.
  • Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 1998 Jun 1;58(11):2339–2342.
  • Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene. 2004 Aug 5;23(35):5978–5985.
  • Cunningham SC, Gallmeier E, Hucl T, et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res. 2006 Jun 1;66(11):5560–5564.
  • Wang P-N, Huang J, Duan Y-H, et al. Downregulation of phosphorylated MKK4 is associated with a poor prognosis in colorectal cancer patients. Oncotarget. 2017;8(21):34352–34361.
  • Finegan KG, Tournier C. The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Res. 2010;70(14):5797–5806.
  • Lu J, Zhou L, Yang G, et al. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. Hum Pathol. 2019 Apr;86:143–154.
  • Troiani T, Napolitano S, Vitagliano D, et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin Cancer Res. 2014;20(14):3775–3786.
  • Misale S, Di Nicolantonio F, Sartore-Bianchi A, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4(11):1269–1280.
  • Little AS, Balmanno K, Sale MJ, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal. 2011;4(166):ra17–ra17.
  • Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3(99):99ra86–99ra86.
  • Martinelli E, Troiani T, D’Aiuto E, et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013;133(9):2089–2101.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.